Matchpoint Therapeutics
Organisation
Funding rounds
Series B
US$150m, 7 Oct 2026
Sources: globenewswire.com
Named in competing interests
Redox activation of ATG5 licenses autophagy upon nutrient restriction
Shares or equity, Founder, Board or leadership role, 24 Sept 2026
Shares or equity, Founder, 4 Nov 2025
Sources: doi.org, pubmed.ncbi.nlm.nih.gov